默沙东(MRK.US)涨逾4% Winrevair在新的肺部适应症中期试验中取得成功

Core Viewpoint - Merck (MRK.US) shares rose over 4% to $96.97 following the announcement of FDA approval for its pulmonary hypertension therapy, Winrevair, which met primary endpoints in patients with pulmonary hypertension [1] Group 1: Drug Approval and Efficacy - Winrevair has shown a significant reduction in pulmonary vascular resistance, achieving the primary endpoint of the Phase 2 CADENCE study with statistical and clinical significance [1] - The study evaluated the efficacy of the injection compared to a placebo in adult patients with pre-capillary and post-capillary pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF) [1] Group 2: Safety and Future Plans - The tolerability of Winrevair is consistent with established safety profiles, indicating a favorable safety profile for the drug [1] - The company plans to present the results at future medical conferences and continue advancing late-stage projects for the drug in CpcPH caused by HFpEF [1]